OasisLMS

2024 ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series

Date of Release: April 8, 2024

Expiration Date: April 8, 2026

Credits offered: 7.0 AMA PRA Category 1 Credits™

Estimate time of completion: 7 hours

Course Description

This course explores the clinical significance of germline and somatic variants in cancer and provides practical knowledge on the application of clinical guidelines and bioinformatics tools for treatment recommendations. Participants will gain an understanding of how various disciplines—medical oncology, molecular pathology, genomics, bioinformatics, and genetic counseling—collaborate in cancer care. Emphasizing the importance of multi-institutional collaboration, the course covers workflows for cancer variant interpretation, including the utilization of genomic tumor boards and variant annotation pipelines.

Target Audience

All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic, VICC, and ACMG consortia.

Webinar Series:

• Highlights from the 2023 ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series
• A Review of Publicly Available Cancer Variant Databases and Knowledgebases
• Adventures in a CHIP Clinic
• Leveraging Large Language Models for Decision Support in Personalized Oncology
• Liquid Biopsy Detection of a TP53 Variant in a “Disease Free” Pediatric Patient: Challenges in Interpretation
• Navigating the Genetic Complexities of Lung Cancer: Case Studies in Germline Variants and Resistance Mutations
• Variant Classification for Disorders of Somatic Mosaicism

Learning Objectives

At the conclusion of this series, participants should be able to:

• Apply clinical guidelines and bioinformatics tools to determine the clinical significance of germline and somatic variants in cancer 
• Describe the spectrum of resources to aid in cancer variant interpretation in the clinic

Meet the Faculty

Manuela Benary, PhD

Bioinformatician

Charité – Universitätsmedizin Berlin, Berlin, Germany

Beth Pitel, MS

Clinical Variant Scientist – Oncology

Assistant Professor of Laboratory Medicine and Pathology

Mayo Clinic

Jason Saliba, PhD

Senior Scientist at Washington University School of Medicine in St. Louis

Presenters:

Moushumi Suryavanshi, M.D., Ph.D., FRCPath

Associate Professor & Head, Molecular Biology

Amrita Institute of Medical Sciences & Research Centre Faridabad, India

Prashant Mehta, DM

Senior Consultant and Program Director

Lymphoid Neoplasms, Cell Therapy, Lung Cancer 

Dept. of Haematology, Medical Oncology and BMT

Amrita Institute of Medical Sciences & Research Centre Faridabad, India

Vidit Kapoor, DM

Consultant

Dept. of Hematology, Medical Oncology and BMT

Amrita Institute of Medical Sciences & Research Centre Faridabad, India

Molly Schroeder, PhD, FACMG

Medical Director, Clinical Genomics Laboratory

Division of Genomic and Molecular Pathology

Washington University School of Medicine in St. Louis

Yang Cao, PhD, FACMG

Associate Professor, Pathology and Immunology

Division of Genomic and Molecular Pathology

Washington University School of Medicine in St. Louis

Kevin Bowling, PhD

Associate Professor, Pathology and Immunology

Division of Genomic and Molecular Pathology

Washington University School of Medicine in St. Louis

Alexa Dickson, PhD

Senior Clinical Variant Scientist, Clinical Genomics Laboratory

Division of Genomic and Molecular Pathology

Washington University School of Medicine in St. Louis

Patrick R. Blackburn, PhD, FACMG

Department of Pathology, St. Jude Children’s Research Hospital

Selene C. Koo, MD, PhD

Department of Pathology, St. Jude Children’s Research Hospital

Manuela Benary, PhD

Bioinformatician
Charité – Universitätsmedizin Berlin, Berlin, Germany

Xing Wang

Second-year PhD student, Humboldt-University in Berlin

Terra Lasho, Ph.D.

Research Scientist – Hematology; Director of the CHIP Clinic

Planning Committee:

Beth Pitel, MS, CG(ASCP)

Gordana Raca, MD, PhD, FACMG

Manuela Benary, PhD

Jason Saliba, PhD

Staff:

Jane Radford, MHA, CHCP

Claudia Barnett 

Accredited Continuing Education Information:

AMA PRA Category 1 Credits^TM

Accreditation

The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
The American College of Medical Genetics and Genomics designates this enduring activity for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Medical Association (AMA) defines physicians as those individuals who have obtained an MD, DO, or equivalent medical degree from another country. Non-physicians may request a certificate of attendance for their participation.

Claiming your Educational Credits

This activity consists of: View content, take a post-test, the test may be taken as often as necessary to achieve a passing score of 80% or better is required to receive credit.  If you do not achieve a passing score, the program will identify which questions you answered incorrectly so that you can review the module and try again. Complete the evaluation form.

Learner Data Consent

ACMG Education reports learner data to respective agency boards and you will be asked for consent during the evaluation process. Your compliance with deadlines and completing evaluations are part of the process in meeting learner needs and ACMG’s education mission.

Technical Support:
You can reach us by email at education@acmg.net or call 301-718-9603.
Support Center Hours: Monday – Friday, 9:00 AM – 5:00 PM Eastern Time.

Accredited Continuing Education Financial Disclosure

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.

ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

ACMG Education Policies

Please review the policies below regarding the ACMG Education program

• Financial Disclosures and Mitigation Procedure
• ACMG Content Validation Policy
• ACMG Content Branding Policy

All of the relevant financial relationships listed for these individuals have been mitigated.

ACMG educational programs are designed primarily as an educational tool for health care providers who wish to increase their understanding of the application of genomic technologies to patient care. The ACMG does not endorse or recommend the use of this educational program to make patient diagnoses, particular by individuals not trained in medical genetics. Adherence to the information provided in these programs does not necessarily ensure a successful diagnostic outcome. The program should not be considered inclusive of all proper procedures and or exclusive of other procedures and that are reasonably directed at obtaining the same results. In determining the propriety of any specific procedure or, a healthcare provider should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen.

Questions regarding CE credit should be directed to education@acmg.net